Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients

Clinical Infectious Diseases

Volumn 23, Issue 5, 1996, Pages 1126-1138

  Wasan, Kishor M ^a   Lopez Berestein, Gabriel ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANNAMYCIN; DEOXYCHOLATE SODIUM; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DOXORUBICIN; LIPOSOME; MEGLUMINE ANTIMONATE; NYSTATIN; POTASSIUM;

CANCER; CANDIDA ALBICANS; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA DONOVANI; LEISHMANIASIS; LIPID COMPOSITION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SURVIVAL;

EID: 0029911039     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.5.1126     Document Type: Review

References (17)

1. Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacology Reviews 1984;36: 277-336.
2. Juliano RJ, Layton D. Characteristics and biomedical applications. In: Juliano RJ, ed. Drug delivery systems. London: Oxford University Press, 1980:189-236.
3. Juliano RL. Liposomes as a drug delivery system. Trends in Pharmacological Sciences 1981;2:39-59.
4. Szoka F, Papahadjopoulos D. Liposomes: preparation and characterization. In: Knight CG, ed. Liposomes: from physical structure to therapeutic applications. Amsterdam: Elsevier-North Hollan, 1981:51-82.
5. Juliano RJ. Drug delivery systems. In: Ostro MJ, ed. Liposomes. New York: Marcel Dekker Press, 1983:53-86.
6. Gregoriadis G. Targeting of drugs: implications in medicine. Lancet 1981; 2:241-6.
7. Gregoriadis G, Allison A. Liposomes as drug delivery systems. In: Gregoriadis G, ed. Liposomes in biological systems. Chichester, England: John Wiley and Sons, 1980:277-301.
8. Poste G. Liposome targeting in vivo: problems and opportunities. Biol Cell 1983;47:19-38.
9. Poste G, Kirsh R. Site-specific (targeted) drug delivery in cancer therapy. Biotechnology 1983;1:869-78.
10. Olson F, Mayhew E, Maslow D, Rustum Y, Szoka F. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. Eur J Cancer 1982;18:167-76.
11. Litzinger DC, Huang L. Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications. Biochim Biophys Acta 1992;1113:201-27.
12. Curr MI, James A. Study of phospholipids. In: Gurr MI, James AT, eds. Lipid biochemistry. 3rd ed. London: Chapman and Hall, 1980:2-22.
13. Lopez-Berestein G. Liposomes as carriers of antifungal drugs. Ann NY Acad Sci 1988;544:590-7.
14. Weinstein JH, Lesserman LD, Henkart PA, Blumenthal R. Antibody mediated targeting of liposomes. In: Weinstein JH, ed. Targeting of drugs. New York: Plenum Press, 1982:185-202.
15. Fendler JH. Optimizing drug entrapment in liposomes: chemical and biophysical considerations. In: Gregoriadis G, ed. Liposomes in biological systems. Chichester, England: John Wiley and Sons, 1980: 87-100.
16. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 1982;42:4734-9.
17. Rahman A, Kessler A, More N, et al. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res 1980;40:1532-7.